pd-1-in-22

PD-1-IN-22 是一种有效的程序性细胞死亡 1 (PD-1) 程序性细胞死亡配体1 (PD-L1) 相互作用的抑制剂，IC50 为 92.3 nM。

PD-1 PD-L1-IN-22 是 PD-1 PD-L1 蛋白-蛋白相互作用的小分子抑制剂，能够阻断 PD-1 PD-L1相互作用 (IC50: 0.732 μM)。PD-1 PD-L1-IN-22 能够用于研究癌症、传染病和自身免疫性疾病。

Beta-MSH (1-22) (human) acetate (Beta-MSH (1-22) (human) acetate (17908-57-5 Free base)) 是一种 22 肽，是一种内源性黑皮质素 4 受体 (MC4-R) 激动剂。

C-Type Natriuretic Peptide (CNP) (1-22), human acetate 是一种利钠肽受体 B (NPR-B) 的激动剂，一种内皮衍生的松弛剂和生长抑制因子。 C-Type Natriuretic Peptide (CNP) (1-22), human acetate 抑制由组胺和 5-HT 或直接由毛喉素刺激的 cAMP 合成。

PD-1-IN-17 是程序性细胞死亡 1 (PD-1) 的抑制剂。 PD-1-IN-17 在 100 nM 时抑制 92% 的脾细胞增殖。

PD-1 PD-L1-IN-9 是一种有效和具有口服活性的 PD-1 PD-L1 相互作用抑制剂，IC50 值为 3.8 nM。PD-1 PD-L1-IN-9 可以增强免疫细胞对肿瘤细胞的杀伤活性。PD-1 PD-L1-IN-9 在 CT26 小鼠模型中表现出显着的体内抗肿瘤活性。

C-Type Natriuretic Peptide (CNP) (1-22), human 是一种利钠肽受体 B (NPR-B) 激动剂，是一种 CNP 的 1-22 片段。它对生理激动剂组胺和 5-HT 刺激或直接由 Forskolin 刺激的 cAMP 合成具有抑制作用。其中CNP 是一种有效的、内皮衍生的松弛剂和生长抑制因子。

RMP1-14 是一种 IgG 样免疫球蛋白抗小鼠 PD-1 抗体，可阻断 PD-1/PD-L1 信号传导。

PD-1-IN-25 (compound 43) 是一种抑制PD-1 PD-L1相互作用的有效化合物，在HTRF测定中显示出10.2 nM的IC50值。此化合物能够阻断PD-1 PD-L1细胞信号传导途径，进而促进CD8+ T细胞的活化，并有效延缓肿瘤生长。

PD-1 PD-L1-IN-32（compound A56）为高效抗PD-1 PD-L1抑制剂，IC50值为2.4 nM，显示出抗癌活性。在hPD-L1 MC38人源化小鼠模型中，该化合物能显著抑制肿瘤生长，同时对小鼠未见明显毒性。

PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of peripheral blood mononuclear cells in co-cultures with PD-L1 expressing cancer cells (PC9 and HCC827 cells). It significantly elevated the release of interferon γ and induced apoptosis in cancer cells, while exhibiting minimal cytotoxicity in healthy cells [1].

C22 Glucosylceramide (d18:1/22:0) is an endogenous glucosylceramide. Glucosylceramides are major constituents of skin lipid membranes where they play a role in maintaining the water permeability barrier. They are precursors in the synthesis of lactosylceramide , as well as oligoglycolipids and gangliosides. Phospholipase A2 (PLA2) type XIIA knockdown increases C22 glucosylceramide (d18:1/22:0) expression in rat brain. It is also increased in the brain, but not the liver or spinal cord, of mice fed a methionine-restricted diet. In human athletes, plasma levels of C22 glucosylceramide (d18:1/22:0) increase during exercise and return to basal levels during recovery. This product contains C22 glucosylceramide (d18:1/22:0) isolated from bovine buttermilk.

PD-1-IN-17 TFA 是程序性细胞死亡-1 (PD-1) 的有效抑制剂，100 nM 的浓度能够抑制 92% 脾细胞增殖。

PD-1 PD-L1-IN-27是一种针对PD-1 PD-L1的有效抑制剂，具有134 nM的IC50值。该化合物表现出具有低T细胞毒性的抗肿瘤活性，并能够激活CD8+T细胞以及减少T细胞耗竭。

Josiphos SL-J009-1 Pd G3 在生命科学相关研究中具有广泛的应用。

Histone H2BK12ac (1-22)-GGK-biotin amide (trifluoroacetate salt) 可用于生命科学领域的相关研究，其产品编号为 T36095。

C22 dihydro 1-Deoxyceramide (m18:0/22:0) is a very long-chain atypical ceramide containing a 1-deoxysphinganine backbone. 1-Deoxysphingolipids are formed when serine palmitoyltransferase condenses palmitoyl-CoA with alanine instead of serine during sphingolipid synthesis.1,2 C22 dihydro 1-Deoxyceramide (m18:0/22:0) has been found in mouse embryonic fibroblasts (MEFs) following application of 1-deoxysphinganine alkyne or 1-deoxysphinganine-d3.3 It has also been found as the most prevalent dihydro deoxyceramide species in mouse brain, spinal cord, and sciatic nerve at one, three, and six months of age.4 |1. Steiner, R., Saied, E.M., Othman, A., et al. Elucidating the chemical structure of native 1-deoxysphingosine. J. Lipid Res. 57(7), 1194-1203 (2016).|2. Alecu, I., Othman, A., Penno, A., et al. Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway. J. Lipid Res. 58(1), 60-71 (2017).|3. Alecu, I., Tedeschi, A., Behler, N., et al. Localization of 1-deoxysphingolipids to mitochondria induces mitochondrial dysfunction. J. Lipid. Res. 58(1), 42-59 (2017).|4. Schwartz, N.U., Mileva, I., Gurevich, M., et al. Quantifying 1-deoxydihydroceramides and 1-deoxyceramides in mouse nervous system tissue. Prostaglandins Other Lipid Mediat. 141, 40-48 (2019).

PD-1 PD-L1-IN-28（化合物3），一种针对PD-1 PD-L1信号通路的免疫检查点抑制剂，其IC50值为0.744 µM，展现出在肿瘤免疫治疗领域的研究潜力。

PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM.

β-Melanocyte Stimulating Hormone (MSH), human (Synonyms: Beta-MSH (1-22) (human)) β-Melanocyte Stimulating Hormone (MSH), human, a 22-residue peptide, acts as an endogenous melanocortin-4 receptor (MC4-R) agonist.

PD-1-IN-20 [476690-36-9] is the less active enantiomer of PD-1-IN-1 [1346528-06-1].

PD-1 PD-L1-IN-31为具高效PD-1 PD-L1抑制能力的化合物（IC50=2.2 nM），能激进IFN-γ分泌及激活外周血单核细胞（PBMC），进而抑制肿瘤细胞生长。

PD-1 PD-L1-IN-14 (compound 17) 是PD-1 PD-L1相互作用的抑制剂（IC50= 27.8 nM）。通过抑制PD-1 PD-L1 相互作用，PD-1 PD-L1-IN-14促进二聚化，内吞作用并降解 PD-L1。

PD-1 PD-L1-IN-17 (Compound P20) 是一种有效的 PD-1 PD-L1 抑制剂 (IC50: 26.8 nM)。PD-1 PD-L1-IN-17 是一种很有前途的先导化合物，能够用于 PD-1 PD-L1 相互作用抑制剂的开发。PD-1 PD-L1-IN-17 具有潜力进行癌症疾病的研究。

PD-1 PD-L1-IN-33 (Compound N11) 是抑制PD-1与PD-L1相互作用的抑制剂，IC50 值为 6.3 nM。该化合物能够促进T细胞的增殖、激活以及浸润肿瘤球，显示出免疫调节和抗肿瘤的活性。

PD-1 PD-L1-IN-26 (Compound II-14) 是一种高效的 PD-1 PD-L1 抑制剂，IC50 为 0.0380 μM。该化合物能够激活肿瘤免疫微环境，通过促进 CD4+ T 细胞向肿瘤组织的浸润。PD-1 PD-L1-IN-26 展示了在癌症治疗研究中的应用潜力。

PD-1 PD-L1-IN-10 是一种口服有效的PD-1 PD-L1抑制剂 (IC50of 2.7 nM)，显示出抗肿瘤活性。

PD-1 PD-L1-IN 5 是一种有效的 PD-1 PD-L1 蛋白 蛋白相互作用抑制剂 (IC50≤100 nM)。

PD-1 PD-L1-IN-20 是一种小分子的 PD-1 PD-L1蛋白-蛋白相互作用抑制剂。PD-1 PD-L1-IN-20 可阻断 PD-1 PD-L1 相互作用 (IC50: 5.29 nM)。PD-1 PD-L1-IN-20 能够用于研究癌症、传染病和自身免疫性疾病。

PD-1 PD-L1-IN-23为一种高效的口服活性PD-1 PD-L1抑制剂，是L7酯类的前药形式。L7为苯并[c][1,2,5]恶二唑衍生物，作为PD-L1抑制剂在生物学上进行评估。PD-1 PD-L1-IN-23在同基因和PD-L1人源化小鼠的肿瘤模型中展现出显著的抗肿瘤效果。

C22 Galactosylceramide is a sphingolipid that has been found in the central nervous system.1,2C22 Galactosylceramide levels are increased in the spinal cord, but not the brain or liver, of mice fed a methionine-restricted diet.1C22 Galactosylceramide has been found in postmortem hippocampus from patients with Alzheimer's disease.2[Matreya, LLC.]

CYP51 PD-L1-IN-1（compound L11）是一种具有抗真菌活性的喹唑啉化合物，作为CYP51（IC50: 0.884 μM）和PD-L1（IC50: 0.083 μM）的双重抑制剂，能够在细胞周期早期引发真菌细胞的凋亡。该化合物还能有效减少IL-2、NLRP3、NF-κBp65等蛋白的细胞内水平，诱导线粒体损伤及ROS积聚，进而导致真菌细胞的破裂和死亡。

PD-1 PD-L1-IN-15 是 PD-1 PD-L1 的有效抑制剂 (IC50: 60.1 nM)，对肿瘤免疫治疗表现出研究潜力。

PD-1 PD-L1-IN-25 是一种 PD-1 PD-L1 互作的抑制剂 (IC50: 16.17 nM)，可有效激活 PBMCs 中 T 细胞的抗肿瘤免疫。PD-1 PD-L1-IN-25 能够用于研究癌症。

PD-1-IN-18 is a PD1 inhibitor of signaling pathway, and acts as an immunomodulator.

PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.

Piscidin-1 (22-42) (TFA) is a highly potent, multi-functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper (Epinephelus coioides).

PD-L1 PD-1-IN-1 (compound 8j) 用于有效抑制PD-L1 PD-1相互作用，其IC50值低于1nM。此化合物在肿瘤抗病研究领域中具有关键意义。

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA), is a 22 amino acid fragment of CNP and functions as an agonist for the natriuretic peptide receptor B (NPR-B). It can inhibit cAMP synthesis, which is induced by histamine, 5-HT, or Forskolin. Additionally, CNP exhibits strong endothelial-derived relaxation properties and acts as a growth inhibitor.

PD-1/PD-L1 Inhibitor 3 acetate (1629654-95-0 Free base) 抑制人 PD-1 与 PD-L1 的结合，IC50 为 9 nM。

PD-1/PD-L1-IN-13 是一种有效的免疫检查点 PD-1/PD-L1抑制剂，对 PD-1/PD- L1 相互作用的 IC50值为 10.2 nM。PD-1/PD-L1-IN-13 在 Hepa1-6 同系小鼠模型中促进 CD8+T 细胞活化并延缓肿瘤生长。

PD-1 PD-L1-IN-29(S4-1)，有效PD-1 PD-L1抑制剂，IC50值为6.1 nM。能够结合PD-L1，破坏PD-1 PD-L1相互作用，诱导PD-L1二聚化与内化，有助于改善其对内质网的定位并促进PD-L1进入内质网，展现出抗癌活性。

PD-1 PD-L1-IN-34（化合物(1S,2S)-A25）能有效地抑制PD-1 PD-L1相互作用，其IC50值为0.029 μM，表现出对PD-L1的选择性结合亲和力，KD值为0.1554 μM。该化合物通过激活免疫微环境来抑制肿瘤生长。

C22 Sphingomyelin is a naturally occurring form of sphingomyelin . Plasma levels of C22 sphingomyelin positively correlate with hepatic steatosis severity in patients with chronic hepatitis C virus (HCV). C22 Sphingomyelin levels are decreased in T-47D mammary epithelial cells and increased in MDA-MB-231 breast cancer cells relative to C16 sphingomyelin .

PD-1 PD-L1-IN-16 是 PD-1 PD-L1 的有效抑制剂 (IC50: 53.2 nM)，对肿瘤免疫治疗表现出研究潜力。

PD-1-IN-17 TFA is a inhibitor of programmed cell death-1 (PD-1) .

PD-1 PD-L1-IN 5 is an inhibitor of PD-1 PD-L1 protein protein interaction (IC50 of ≤100 nM).

PROTAC PD-1 PD-L1 degrader-1 是一种降解 PD-L1 的 PROTAC，抑制 PD-1 PD-L1 相互作用（IC50：39.2 nM）。PROTAC PD-1 PD-L1 degrader-1 可恢复 Hep3B OS-8 hPD-L1 和 CD3 T 细胞共培养模型中被抑制的免疫力，可通过溶酶体依赖性方式降低 PD-L1 的蛋白质含量。